Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by Singletonon Apr 12, 2004 10:40pm

446 Views

Post# 7345959

RE: k20 .its demand vs limited supply, my friend

Settlement ShortInterest Avg DailyShare Vol. Mar. 15, 2004 28,813 313,824 Feb. 13, 2004 22,340 114,358 Jan. 15, 2004 18,192 75,109 Dec. 15, 2003 11,617 112,678 Nov. 14, 2003 29,010 228,040 Oct. 15, 2003 20,275 187,571 Sep. 15, 2003 13,044 115,574 Aug. 15, 2003 11,030 41,947 Jul. 15, 2003 10,514 73,433 1.00 Jun. 13, 2003 11,014 244,965 1.00 May 15, 2003 11,664 131,867 1.00 Apr. 15, 2003 10,015 6,769 1.48

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages